november AG
november AG english
november AG Annual General Meeting
Corporate-news announcement sent by DGAP.
The sender is solely responsible for the contents of this announcement.
——————————————————————————–
Supervisory board re-elected with great approval / business development
executive leaves company for biotech start-up
Erlangen, 27 May 2003. On today’s 7th annual general meeting, the shareholders
of november AG (ISIN DE0006762909) have re-elected the incumbent supervisory
board. First elected in December 2002, the members of the supervisory board have
now been appointed for four more years until 2007. The members of the old and
new supervisory board are Günter Frankenne, Horst Linn, Prof. Dr. Dr. h.c. Karl
Wilhelm Pohl, Dr. Werner J. Schönfeld, Walter Schurmann, and Dr. Leo Steib.
The company also announced that Dr. Thomas Schulze, member of the Executive
Board, will leave the company effective as of 1 July 2003 for a CEO position
with a biotech start-up company.
Dr. Schulze joined november AG in December 1999. Since November 2001, he was
member of the Executive Board where he was responsible in particular for
Business Development.
Prof. Dr. Dr. h.c. Karl Wilhelm Pohl, Chairman of the Supervisory Board: “The
supervisory board very much regrets that Dr. Schulze is leaving the company. In
the past years, he has played a major role in the shaping of the business units
diagnostics, product security, and therapy, e.g. by gaining strategic reference
customers like the pharmaceutical company Bristol-Myers Squibb GmbH or Hueck, a
leading manufacturer of technical films, for the product security solutions
within the identify Technologies unit. While following his request we would like
to thank him very much for his accomplishments and wish him great success on
his new appointment.”
Currently, filling of the Board position with november AG is not planned. “We
want to reflect the streamlined organizational structure that was established in
the last year on Board level, too”, says Dr. Wolf M. Bertling, CEO of november
AG. He adds: “With a well-established network of industrial development and
sales partners, november AG will continue to successfully commercialize its
innovative products.”
For further information please contact:
Dr. Peer Nils Schröder
november AG – Public Relations/Investor Relations
Ulrich-Schalk-Str. 3
D-91056 Erlangen
Tel.: +49 (0)9131 750 88 868
Fax: +49 (0)9131 750 88 899
e-mail: schroeder@november.de
www.november.de
november AG Gesellschaft für Molekulare Medizin, Erlangen (Germany), is a listed
biotech company (ISIN DE0006762909, Prime Standard Segment of Deutsche Börse)
that develops integrated systems for near patient nucleic acid testing (business
unit directif Diagnostic Solutions) as well as innovative system solutions for
industrial product security and brand protection (identif Technologies).
end of message, (c)DGAP 27.05.2003
——————————————————————————–
WKN: 676290; ISIN: DE0006762909; Index:
Listed: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin-
Bremen, Düsseldorf, Hannover, München und Stuttgart
271622 Mai 03
Latest News
Latest Reports
Upcoming Events
No Events found
Webcasts
No Webcasts found